Conclusion
In summary, our studies have identified a novel mechanism of the proteasome inhibitor ixazomib induced proliferation inhibition and apoptosis in ESCC. It is possible that this effect be mediated by c-Myc/NOXA pathway, which might give a new insight into the anti-tumor effect and mechanism of ixazomib in ESCC.